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Background: To evaluate the effect of high dose statin therapy on lipoprotein associated phospholipase A2 (Lp-PLA2) and secretory phospholipase 
A2 (sPLA2) in acute coronary syndrome (ACS). Lp-PLA2 and sPLA2 are biomarkers of increased cardiovascular risk and targets of emerging 
therapeutic agents but the effect of statin therapy on their levels in patients with ACS is not established.
Methods: Lp-PLA2 and sPLA2 mass and activity were measured in the Myocardial Ischemia Reduction with Acute Cholesterol Lowering (MIRACL) 
trial at baseline and after 16 weeks of atorvastatin 80 mg/day or placebo.
Results: Compared to placebo in a Wilcoxon rank-sum test, atorvastatin treatment resulted in significant(p<0.001) reductions in median Lp-PLA2 
(mass: -35.7 vs. -6.1%; activity:-24.5 vs. 5.5%) and sPLA2 (mass: -32.2 vs. -23.1%, activity: -29.6 vs. -19.2%). Baseline levels of Lp-PLA2 mass 
and activity correlated modestly (r=0.46, p<0.001), whereas sPLA2 mass and activity correlated strongly (r=0.79, p<-0.001). Baseline and 16 
week sPLA2 activity, but not sPLA2 mass, was weakly correlated with Lp-PLA2 activity (r=0.12, p<0.001) and mass (r=0.18, p<0.001). The baseline 
levels of Lp-PLA2 and sPLA2 mass and activity were not associated with subsequent ischemic events. However, subjects with subsequent ischemic 
events had significantly smaller reductions in Lp-PLA2 mass (-15.5 vs. -20.6% p=0.01), sPLA2 mass (-18.9 vs. -28.8% p<0.001) and sPLA2 activity 
(-16.8 vs. -25.2% p<0.001) compared to those without ischemic events. The difference remained significant after adjusting for change in LDL-C and 
baseline sPLA2 or Lp-PLA2.
Conclusions: High dose atorvastatin treatment significantly reduces Lp-PLA2 and sPLA2 mass and activity in patients with ACS. A blunted reduction 
in Lp-PLA2 mass or sPLA2 mass and activity in response to atorvastatin was associated with increased risk of ischemic events.
